This inventor holds 18 USPTO granted patents and 10 published patent applications and 4 EPO patents, primarily in Pharmaceutical Innovations. Top assignees: Genentech, Inc., Curis, Inc., The University of Texas System. Active years: 1996-2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- So. San Francisco, CA (US) (1996)
- South San Francisco, CA (US) (1998 - 2014)
- Millbrae, CA (US) (2003 - 2017)
Company Filing History:
17 out of 3,302 
3 out of 141 
2 out of 5,644 
Years Active: 1996-2017
Areas of Expertise:
Title: **Mark E Reynolds: Innovator in Cancer Therapeutics**
Introduction
Mark E Reynolds, an acclaimed inventor based in Millbrae, California, has made significant contributions to the field of cancer therapeutics through his innovative research. Holding 18 patents, Reynolds has focused on developing novel compounds that aim to manage and treat malignancies effectively.
Latest Patents
Among his recent inventions is the patent for "Pyridyl inhibitors of hedgehog signalling." This invention offers new inhibitors of hedgehog signaling, crucial for developing therapeutic agents targeting specific malignancies. These compounds have a defined general formula, which is vital in their application.
Another noteworthy patent is for "Nemorubicin metabolite and analog reagents, antibody-drug conjugates, and methods." This invention revolves around antibody-drug conjugate compounds designed to be covalently attached to antibodies, enhancing their effectiveness in diagnosing and treating cancer and various diseases through targeted delivery of therapeutics.
Career Highlights
Throughout his career, Mark E Reynolds has made substantial contributions while working with prominent companies such as Genentech, Inc. and Curis, Inc. His work in these reputed organizations has been instrumental in translating innovative ideas into practical solutions in the healthcare sector.
Collaborations
Reynolds has had the pleasure of collaborating with esteemed colleagues such as Mark S Stanley and Daniel P Sutherlin. These professional relationships have undoubtedly enhanced the research efforts in which he has been involved, allowing for shared knowledge and expertise in their respective fields.
Conclusion
Mark E Reynolds continues to be a significant figure in the world of cancer research and therapeutics, with an impressive portfolio of patents and a career marked by collaboration and innovation. His contributions pave the way for new treatment options for malignancies, showcasing the power of invention in addressing critical health challenges.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile